Abstract
This article has been retracted. The retraction notice was published on 06 May 2020: Retraction notice: Daily versus post-dialysis administration of calcimimetics for the treatment of secondary hyperparathyroidism in haemodialysis patients: an interventional, multi-centre study. Afr J Nephrol. 2020; 2391):85.
Highlights
The treatment of secondary hyperparathyroidism (SHPT) and the mineral and bone disorder ofD chronic kidney disease (CKD–MBD) in patients on chronic haemodialysis (HD) may be hampered by poor adherence to medication
Intact parathyroid hormone (PTH), C serum calcium, phosphorus and alkaline phosphatase levels, dosage of phosphate binders and vitamin D analogues were compared at baseline and 6 months after initiation of thrice weekly calcimimetic dosing
Compared to daily dosing, thrice weekly calcimimetic dosing after HD was more effective in controlling
Summary
The aim of this study was to assess the effectiveness of supervised, post-HD administration of calcimimetics in controlling markers of CKD–MBD in these patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
